Avid Bioservices Inc (CDMO)

[biopharm]

BeiGene <> Jedd Wolchok <> Peregrine Pharmaceuticals

There are so many collaborations, as Steve King-CEO of Peregrine Pharmaceuticals had told us 2 years ago there were "dozens" and some doubted it (probably the same ones that are still so negative on Peregrine today). Since that time, we have now been told about MSK, to AstraZeneca, to NCCN and since I really don't like some getting fooled out there and allowing shares slip out of their hands.... just try to connect the dots with all the posts from the past.

I'll toss a little nugget in there again. MSK and Peregrine certainly attracted the attention of MSK Jedd Wolchok and how long was it after that did it take BeiGene to bring him on board? ... less than 4 months later. Now go back and read the prior post this is attached to and look at the secrecy of BeiGene and Peregrine... and read the words from Dr. Wolchok himself..

Hold them shares tight... someone is coming to get them... or have been trying : )

--------------------------------------------------------

May 29, 2015

Peregrine Pharmaceuticals Enters Into Research Collaboration to Investigate Novel PS-Targeting Immunotherapy Combinations

Research Collaboration to Focus on Exploring Potential Combinations of PS-Targeting Agents Including Bavituximab With Other Immune Modulators
...
..
The studies at MSK will be performed under the direction of Taha Merghoub, Ph.D., Associate Attending Biologist, Melanoma and Immunotherapeutics Service, Ludwig Collaborative and the Swim Across America Laboratory, a part of the laboratory of Jedd D. Wolchok, M.D., Ph.D., a leader in the field of cancer immunotherapy. Dr. Wolchok serves as the Chief, Melanoma and Immunotherapeutics Service, Lloyd J. Old Chair for Clinical Investigation as well as an Associate Director of the Ludwig Center for Cancer Immunotherapy at MSK.

"The phosphatidylserine (PS) signaling pathway is a very interesting target for modulating the immune system's response to cancer. We look forward to exploring the potential of PS-targeting agents alone and with other immune modulators that may lead to novel advances in cancer therapy," said Dr. Wolchok.
..
..
"A key focus of the Wolchok Lab's research is studying novel immunotherapy combinations that work together to enable the immune system to recognize and destroy cancer. This collaboration will allow us to focus on the role and contribution of PS blockade therapy in determining which combination of the current and next generation of immune modulators is likely to increase the extent and amplitude of anti-tumor response. This important pre-clinical and translational work will potentially guide the design of the next generation of clinical studies with bavituximab," said Dr. Merghoub.

"We are delighted to be working with a world-renowned pioneer and leader in the immuno-oncology space, recognizing that there remains significant research in order for more cancer patients to realize the benefits of combination immune therapy," said Jeff T. Hutchins, Ph.D., VP of Preclinical Research at Peregrine. "Our internal and collaborative research presented over the last year has established a robust foundation of PS-targeting activity on which to initiate this next chapter in PS research and development."
...
..

http://ir.peregrineinc.com/releasedetail.cfm?ReleaseID=915472

Sept 11, 2015

BeiGene Announces the Addition of Dr. Jedd D. Wolchok to Scientific Advisory Board

..
..
"I am delighted to join BeiGene's Scientific Advisory Board and look forward to working with this team," said Dr. Wolchok. "The company has a robust research engine and has successfully brought four exciting drug candidates into clinic that may have the potential to be more effective in combination."
..
..

https://globenewswire.com/news-release/2015/09/11/767726/10149045/en/BeiGene-Announces-the-Addition-of-Dr-Jedd-D-Wolchok-to-Scientific-Advisory-Board.html

and we still have Dr Raymond Birge stepping up to the plate.... let the Bavi battles begin : )